FlintLaw – Xarelto
The Dangers of Invokana and Invokamet Use
Invokana, Invokamet and Invokament XR contain canagliflozin, a drug developed for the treatment of Type II diabetes. Invokana® works by blocking an integral membrane protein, sodium-glucose co-transporter 2 (SGLT2 inhibitors), from putting sugar removed by the kidneys back in the bloodstream.
On May 15, 2015, the FDA issued a warning that certain SGLT2 diabetes drugs, including canagliflozin, may lead to ketoacidosis, a potentially life-threatening complication with symptoms of abdominal pain, vomiting, weakness, gasping breaths, increased urination, confusion and occasional loss of consciousness.
On May 16, 2017, the FDA issued a drug safety communication requiring a boxed warning for an increased risk of amputations. The FDA concluded that, based on two large clinical trials, canagliflozin caused an increased risk of foot and leg amputations.
An FDA advisory committee has also expressed concern about the association of canagliflozin with heart attacks and strokes.
Patients taking Invokana should alert their health care professional immediately if they develop new pain or tenderness, sores or ulcers, or infections of the legs or feet.
Invokana and Invokamet Side Effects
If you have Type 2 diabetes and suffered any of the following while on Invokana, please call our firm:
- Toe, foot, or leg amputation
- Kidney Damage
- Myocardial Infarction
*Never stop taking a drug without first consulting your doctor.